

PERSONAL INFORMATION

Johann Lodewijk Hillege

WORK EXPERIENCE

-
- 1983–1990 **Lecturer anatomy, physiology, first aid and hygiene**
Municipality of Leeuwarden (Netherlands)
Lecturer
- 1984–1990 **Student assistant**
University of Groningen, Broerstraat 5, 9700 AB, Groningen (Netherlands)
Lecturer
- 1989–1995 **Clinical research physician**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groninge (Netherlands)
Research Physician
- 1995–1997 **Projectleader coronary and endovascular stents**
Cordis Europa NV, Oosteinde 8, 9301LJ Roden (Netherlands)
Project leader clinical evaluations
- 1997–1998 **Director Endovascular**
Cordis Europa NV, Oosteinde 8, 9301LJ Roden (Netherlands)
Member of the management board, head of the clinical evaluation of medical devices
- 1998–2001 **Department of Clinical Pharmacology**
University of Groningen, Broerstraat 5, 9700 AB, Groningen (Netherlands)
Lecturer
- 1998–Present **Clinical assessor**
Dutch Medicines Evaluation Board, Graadt van Roggenweg 500 3531 AH Utrecht (Netherlands)
Clinical regulatory assessment of medicines and devices
- 2001–2013 **Clinical research**
Trial Coordination Centre, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen (Netherlands)
Director, general management
- 2004–2007 **Assistant professor**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen (Netherlands)
Clinical research
- 2007–Present **Professor**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB

Groningen (Netherlands)
Clinical research

September 2013–September
2016

Alternate CHMP member

Dutch Medicines Evaluation Board (Netherlands)
Clinical regulatory assessment of medicines

September 2016–Present

CHMP member

Dutch Medicines Evaluation Board (Netherlands)

EDUCATION AND TRAINING

1978–1982

Teacher in Physical Education

Academy of physical education, Groningen (Netherlands)
Teaching

1982–1990

Medical doctor

University of Groningen, Medical Faculty, Broerstraat 5, 9700 AB, Groningen (Netherlands)
Medical doctor

1990–1992

Statistical analyst

Netherlands Society for Statistics and Operation Research (Netherlands)
Statistical analyst

1998–2002

PhD

University of Groningen, Department of Clinical Pharmacology, Broerstraat 5, 9700 AB, Groningen (Netherlands)
Thesis "Renal risk markers in cardiovascular disease"

1991–1993

Master of Science in Epidemiology

Netherlands Epidemiological Society (Netherlands)
Master of science

ADDITIONAL INFORMATION**Expertise**

Regulatory Clinical assessment of medicines and devices
Cardiology
Nephrology
Epidemiology and statistics
Clinical Pharmacology

Publications

Selected peer-reviewed publications
- > 400 publications and contribution to book chapters
- Web of Knowledge h-index: 65 (Hillege OR Hillige)
- Average impact factor of my publications: > 2
- Impact factor of the leading journal in my field (J Am Coll Cardiol): 19.896
- Examples of some publications:

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. *Oncologist*. 2017 Oct 27. pii: theoncologist.2017-0257.

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions. Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S. *Clin Pharmacol Ther*. 2015 Nov;98(5):522-33

Do European Patients Have a Shared Preference For The Benefits And Risks Of Medicines? Beyer A, Kingma B, Hoekstra T, Fasolo B, Hillege JL. *Value Health*. 2015 Nov;18(7)

Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessors. Beyer AR, Fasolo B, de Graeff PA, Hillege HL. *Value Health*. 2015 Jan;18(1):91-9

Risk Perception of Prescription Drugs: Results of a survey among experts in the European Regulatory Network Beyer A, Fasolo B, Phillips LD, de Graeff PA, Hillege HL. *Med Decis Making*. 2013 May;33(4):579-92.

Brain Natriuretic Peptide and Prognosis in Heart Failure Patients with Preserved and Reduced Ejection Fraction van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JGP, Paulus WJ, Voors AA, Hillege HL. *J Am Coll Cardiol*. 2013 Apr 9;61(14):1498-506

Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. *Eur J Heart Fail*. 2012 Feb;14(2):168-75.

de Boer RA, Schrotten NF, Bakker SJ, Mahmud H, Szymanski MK, van der Harst P, Gansevoort RT, van Veldhuisen DJ, van Gilst WH, Hillege HL. Plasma renin and outcome in the community: data from PREVEND. *Eur Heart J*. 2012 Sep;33(18):2351-9.

Projects

2002 - De Cock Foundation - Pathophysiological relationships and prognostic properties of increased levels of urinary albumin excretion in heart failure

2006 - The Netherlands Heart Foundation - Progressive loss of renal function and its cardiac-hemodynamic and neurohormonal determinants in heart failure patients; a time course study

2006 - Zesde Kaderprogramma - Workpackage leader in Applied Genomic Strategies for treatment and the prevention of cardiovascular death in uremia and end-stage renal disease project.

2006 - Ti Pharma - Workpackage leader in The Escher Project: Science driven drug regulation and innovative research throughout phased drug development

2008 - Workpackage leader in the Triumph project, translational Initiative on Unique and novel strategies for Management of Patients with Heart failure

2008 - Principal investigator ARIANA-CHF-RD, a double-blind, placebo-controlled, investigator initiated, randomized trial investigating the safety and efficacy of additive renin inhibition with aliskiren on renal blood flow and neurohormonal activation in patients with chronic Heart failure and renal dysfunction

2009- In-Touch. The INTOUCH study is a VWS sponsored study investigating the added value of Telecare and disease management in patients with severe heart failure.

2010 - Workpackage leader in Bioshare-eU FP7-HEALTH . Biobank Standardisation and Harmonisation for Research Excellence in the European Union

2010 - The Netherlands Heart Foundation – Prognostic properties of temporal changes in electrocardiograms

2010 - Workpackage leader BIOSTAT-CHF FP7-HEALTH A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure

2013 - Extension of the IMI Protect Work Package 6

2014 - Get Real IMI

2016 - ReConnect Dutch Heart Foundation

Memberships

Netherlands Society of Cardiology

European Society of Cardiology

European Working Group of Heart Failure

Other Relevant Information